Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical application of anhydroicaritin

A technology for the use of icariin, which is applied in the field of medicine, can solve the problems of myelodysplastic syndrome without icariin, and achieve the effect of improving peripheral blood abnormal hematopoiesis, good therapeutic effect, and significant therapeutic effect

Active Publication Date: 2015-04-29
LUNAN PHARMA GROUP CORPORATION
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent application CN101637466A discloses the application of icariin in the preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases, and Chinese patent application CN101637467A discloses the application of icariin in the preparation of drugs for treating osteoporosis, but the prior art does not There is no report on the treatment of myelodysplastic syndrome with icarigenin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of anhydroicaritin
  • Medical application of anhydroicaritin
  • Medical application of anhydroicaritin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Embodiment 1 icarigenin injection

[0015]

[0016] Preparation process: Mix the prescribed amount of propylene glycol and ethanol evenly, add icariin, stir to dissolve, add the prescribed amount of 0.9% sodium chloride solution, stir evenly, add 0.5% activated carbon for needles, stir, decarbonize, that is have to.

Embodiment 2

[0017] Example 2 Icarigenin Injection

[0018]

[0019] Preparation process: Add icariin to the prescribed amount of PEG-400, stir to dissolve, add 0.9% sodium chloride solution to 10L, stir evenly, add 0.5% activated carbon for needles, stir, decarbonize, and obtain.

Embodiment 3

[0020] Example 3 Icarigenin Injection

[0021]

[0022] Preparation process: Mix the prescribed amount of ethanol and Tween-80 evenly, add icariin, stir to dissolve, add water for injection to 10L, stir evenly, add 0.5% activated carbon for needles, stir, decarbonize, and obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of anhydroicaritin in preparation of medicine curing or preventing myelodysplastic syndrome, and belongs to the field of medicine. The anhydroicaritin is traditional Chinese medicine monomer extracted from conventional traditional Chinese medicine epimedium, and can remarkably increase peripheral blood hemocyte amount and improve peripheral blood dyshaematopoiesis when the anhydroicaritin is used for curing a myelodysplastic syndrome patient; the curative effect of the anhydroicaritin is superior to that of an epimedium extractive and icariin; the anhydroicaritin is definite in curative effect and low in side effect when being used for curing myelodysplastic syndrome, and has a wide medical application prospect.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a medical use of icariin, in particular to the medical use of icariin in preparing medicines for treating or preventing myelodysplastic syndrome. Background technique [0002] Myelodysplastic syndrome (Myelodysplastic syndrome, MDS) refers to various types of hematopoietic stem cell diseases. MDS is characterized by impaired morphology and maturation of the cellular marrow (dysmyelopoiesis), peripheral blood cytopenias, and a variable risk of developing acute leukemia caused by failure of hematopoiesis. It is due to a variety of physical and chemical factors, such as alkylating agents, benzene compounds, ionizing radiation, etc., which damage the hematopoietic stem cells, resulting in ineffective hematopoiesis, and then the reduction of the first, second or third line of blood. MDS can occur in any age group, but the highest incidence rate is over the age of 60. Approximately 15,000 new M...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P7/00
CPCA61K31/352
Inventor 赵志全李春燕徐真真李敏
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com